Barinthus Biotherapeutics Pte Ltd. (BRNS)
Summary
Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) Upgraded to Buy: What Does It Mean for the Stock?
Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) Upgraded to Strong Buy: Here's Why
Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Barinthus Biotherapeutics Pte Ltd. (BRNS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Barinthus Biotherapeutics Pte Ltd. ever had a stock split?
Barinthus Biotherapeutics Pte Ltd. Profile
| Biotechnology Industry | Healthcare Sector | William James Enright CEO | NASDAQ (NMS) Exchange | 91864C107 CUSIP |
| GB Country | 105 Employees | - Last Dividend | - Last Split | 30 Apr 2021 IPO Date |
Overview
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company focused on pioneering T cell immunotherapeutic candidates targeted at chronic infectious diseases, autoimmunity, and cancer. With its inception in 2016 and headquarters in Didcot, the United Kingdom, the company has positioned itself at the forefront of developing therapies aimed at guiding the immune system to conquer these health challenges. Originally known as Vaccitech plc, the company underwent a name change to Barinthus Biotherapeutics plc in November 2023, reflecting its evolving focus and ambition in the biopharmaceutical landscape. Through its comprehensive development pipeline and strategic collaborations with leading medical research institutions and pharmaceutical companies, Barinthus Biotherapeutics is committed to advancing healthcare and offering new treatments that promise to enhance patient outcomes significantly.
Products and Services
- VTP-300: This is an immunotherapeutic candidate undergoing phase 2 studies, aiming to serve as a functional cure for chronic hepatitis B virus (HBV) infection. It exemplifies the company's efforts in addressing chronic infections through innovative immune system engagement.
- VTP-200: Currently under phase 2 studies, VTP-200 is a non-surgical product candidate focused on the treatment of persistent high-risk human papillomavirus (HPV) infection. This development reflects the company's commitment to addressing sexually transmitted infections with novel therapeutic approaches.
- VTP-1000: In the preclinical stage, VTP-1000 is designed to treat patients with celiac disease, showcasing Barinthus Biotherapeutics’ endeavors into autoimmunity with an aim to provide relief to patients from autoimmune afflictions.
- VTP-1100: Targeting HPV16+ cancers, this product candidate is part of the company’s oncology pipeline. Barinthus Biotherapeutics’ efforts in cancer immunotherapy highlight its commitment to combating cancer with revolutionary T cell-directed treatments.
- VTP-850/850: Under phase 2 studies to treat recurrent prostate cancer, this second-generation immunotherapeutic candidate signifies the company's forward movement in leveraging immune system modulators for cancer treatment.
- Partnered Candidates: These include AB-729-202, a phase 2a study candidate for chronic HBV infection; VTP-600, an immunotherapy candidate for NSCLC in combination with chemotherapy and pembrolizumab, currently under phase 1 studies; VTP-500, a prophylactic vaccine candidate aimed at preventing infection caused by the MERS coronavirus, also under phase 1 studies; and VTP-400, a preventive vaccine candidate for shingles in adults, which is in the phase 1 study stage.
- Vaxzevria (formerly VTP-900 and AZD1222): This prophylactic vaccine for COVID-19 prevention highlights the company's rapid response to global health emergencies and its ability to contribute significant solutions in the fight against pandemics.
